-

NRX PHARMACEUTICALS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of NRx Pharmaceuticals, Inc. - NRXP

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into NRx Pharmaceuticals (NasdaqGM: NRXP).

In June 2021, the Company announced that it filed an application with U.S. Food and Drug Administration (“FDA”) requesting Emergency Use Authorization (“EUA”) for Zyesami, its investigational pre-commercial drug product for treating COVID-19 related respiratory failure. Then, on November 4, 2021, the Company disclosed that the FDA had declined to issue an EUA for Zyesami “due to insufficient data regarding the known and potential benefits of the medicine and the known and potential risks of Zyesami in patients suffering from Critical COVID-19 with respiratory failure.”

The Company was subsequently sued in a securities class action lawsuit for failing to disclose material information, violating federal securities laws, which remains ongoing.

KSF’s investigation is focusing on whether NRx’s officers and/or directors breached their fiduciary duties to the Company’s shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of NRx shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgm-nrxp/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163

Kahn Swick & Foti, LLC

NASDAQ:NRXP

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163

More News From Kahn Swick & Foti, LLC

Golden Entertainment Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Golden Entertainment, Inc. - GDEN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Golden Entertainment, Inc.’s (NasdaqGM: GDEN) operating assets to Blake L. Sartini and affiliates, and seven of its casino real estate assets to VICI Properties Inc. (NYSE: VICI). Under the terms of the proposed transaction, shareholders of Golden will receive a fixed exchange ratio of 0.902 shares...

SWK Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SWK Holdings Corporation - SWKH

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SWK Holdings Corporation (the “Company”) (NasdaqGM: SWKH) to Runway Growth Finance Corp. (NasdaqGS: RWAY). Under the terms of the proposed transaction, the merger consideration will be determined by each company’s estimated net asset value calculated under ASC 946 shortly before closing, setting an...

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Arcellx, Inc. (NasdaqGS: ACLX) to Gilead Sciences, Inc. (NasdaqGS: GILD). Under the terms of the proposed transaction, shareholders of Arcellx will receive $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones. KSF is seeking to deter...
Back to Newsroom